<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02161653</url>
  </required_header>
  <id_info>
    <org_study_id>DI/10/107/3/43</org_study_id>
    <nct_id>NCT02161653</nct_id>
  </id_info>
  <brief_title>Metadoxine as a Therapy for Severe Alcoholic Hepatitis</brief_title>
  <official_title>Impact of Metadoxine in the Oxidative Stress and Early Mortality in Patients With Severe Alcoholic Hepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General de Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital General de Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether metadoxine is effective for improve
      survival and reduced oxidative stress in patients with severe alcoholic hepatitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30 day-survival</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Malondialdehyde serum levels</measure>
    <time_frame>14 and 30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>3 month-survival</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 month-survival</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Severe Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>Prednisone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Prednisone 40 mg daily by mouth during 30 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pentoxifylline</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Pentoxifylline 400 mg thrice in day by mouth during 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisone plus metadoxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prednisone 40 mg daily by mouth plus Metadoxine 500 mg thrice in day by mouth during 30 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pentoxifylline plus metadoxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pentoxifylline 400 mg thrice in day by mouth plus Metadoxine 500 mg thrice in day by mouth during 30 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone plus Metadoxine</intervention_name>
    <arm_group_label>Prednisone plus metadoxine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentoxifylline plus Metadoxine</intervention_name>
    <arm_group_label>Pentoxifylline plus metadoxine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with clinical and biochemical criteria for severe alcoholic hepatitis: Total
             bilirubin greater than 5 mg/dl in absence of biliary tract obstruction evidenced by
             ultrasound, history of chronic alcohol intake, leukocytosis, neutrophilia, elevation
             of transaminases with an aspartate aminotransferase / alanine aminotransferase ratio
             equal or greater than 2, discriminant function greater than 32.

        Exclusion Criteria:

          -  Diabetes, chronic kidney disease, hepatitis C, hepatitis B and or human
             immunodeficiency virus infection, asthma or history of atopy or allergic reactions,
             therapy in the previous two years with steroids, pentoxifylline, metadoxine,
             S-adenosyl L- methionine, antioxidants or multivitamins.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital General de Mexico</name>
      <address>
        <city>Mexico City</city>
        <state>D.f.</state>
        <zip>06726</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2014</study_first_submitted>
  <study_first_submitted_qc>June 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2014</study_first_posted>
  <last_update_submitted>November 8, 2014</last_update_submitted>
  <last_update_submitted_qc>November 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General de Mexico</investigator_affiliation>
    <investigator_full_name>MARIA DE FATIMA HIGUERA DE LA TIJERA</investigator_full_name>
    <investigator_title>MD, MSc.</investigator_title>
  </responsible_party>
  <keyword>Severe alcoholic hepatitis</keyword>
  <keyword>survival</keyword>
  <keyword>oxidative stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Pentoxifylline</mesh_term>
    <mesh_term>Metadoxine</mesh_term>
    <mesh_term>Pyridoxine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

